A judge has granted a request by Otsuka and Bristol-Myers Squibbs to withdraw admissions in proceedings brought by Generic Health seeking damages, after the generic drug maker was temporarily blocked from selling a generic version of antipsychotic Abilify in a patent dispute in which it ultimately triumphed.
Medtronic owned Covidien and two other medical device manufacturers have been hit with a class action on behalf of thousands of women who claim to have suffered lifelong complications from the devices, the third class action over pelvic mesh implants brought in Australia.
A judge overseeing patent litigation over the painkiller Dynastat has urged the parties to narrow any issues in dispute, saying the excessive amounts of money spent in these types of cases could harm public perception.
The former CEO of Respiri has levelled a slew of claims at the ASX-listed medical technology company and two of its former directors, including breach of the Fair Work Act, as well as failure to pay short term incentives (STI) and vest options valued at $2.2 million.
An Adelaide lawyer has been awarded $750,000 in damages after suing a woman who gave him bad reviews on Google that sent 80 per cent of his clients packing.
Two biotech companies that provide molecular diagnostic products used in genetic screening will face off in Federal Court over whether one of the company’s ‘Access’ trade mark is likely to confuse consumers.
The international company behind the Vagisil feminine hygiene brand has lost its bid to stop a European competitor from registering Vagisan as a trade mark in Australia.
The Fair Work Commission has dismissed a general protections dispute brought by an “agoraphobic” beautician after social media posts revealed an active social life including gin, Greek food and the Melbourne Cup.
Bupa has launched court action to block a directive by the Aged Care Quality and Safety Commission as the aged care provider battles a separate case by the ACCC over payments allegedly charged to residents for services they did not receive.
German drug company Fresenius Kadi has resolved a patent case brought by Korean drug company Samsung Bioepis over a biosimilar of top selling arthritis drug Humira.